(FOLD) Amicus Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 4.534m USD | Total Return: 102.1% in 12m
Rare Disease Drugs, Gene Therapy
Total Rating 52
Safety 34
Buy Signal 0.92
Biotechnology
Industry Rotation: +3.6
Industry Rotation: +3.6
Market Cap:
4.53B
Avg Turnover: 43.1M USD
Avg Turnover: 43.1M USD
ATR:
0.22%
Peers RS (IBD): 66.8
Peers RS (IBD): 66.8
Risk 5d forecast
Volatility1.98%
Rel. Tail Risk-10.2%
Reward TTM
Sharpe Ratio1.38
Alpha64.81
Character TTM
Beta0.898
Beta Downside1.056
Drawdowns 3y
Max DD61.16%
CAGR/Max DD0.14
EPS (Earnings per Share)
EPS CAGR: 131.02%
EPS Trend: 83.6%
EPS Trend: 83.6%
Last SUE: -0.52
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 25.63%
Rev. Trend: 97.6%
Rev. Trend: 97.6%
Last SUE: 0.04
Qual. Beats: 0
Qual. Beats: 0
Warnings
High Debt/EBITDA (5.0) with thin interest coverage (1.0)
Altman Z'' -10.37 < 1.0 - financial distress zone
Tailwinds
Supp Ema20
Description: FOLD Amicus Therapeutics
Amicus Therapeutics, Inc. (FOLD) is a biotechnology company specializing in therapies for rare diseases. The companys business model centers on developing and commercializing novel medicines for conditions with limited treatment options.
Their key commercial product is Galafold, an oral treatment for Fabry disease. They also have product candidates like Pombiliti + Opfolda for Pompe disease and DMX-200, currently in Phase 3 trials for FSGS kidney disease. The biotechnology sector often involves lengthy and costly drug development processes.
Amicus engages in strategic collaborations, such as agreements with GlaxoSmithKline for Galafold and Dimerix Limited for DMX-200. These partnerships are common in the pharmaceutical industry to share development costs and expand market reach.
Further research on ValueRay can provide detailed financial metrics and competitive analysis.
- Galafold sales growth drives primary revenue expansion
- Pompe disease treatment launch impacts future revenue
- DMX-200 clinical trial results influence pipeline value
- Regulatory approval timelines affect drug commercialization
- Research and development expenses impact profitability
Piotroski VR‑10 (Strict)
5.0
| Net Income: -27.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 7.91 > 1.0 |
| NWC/Revenue: 69.12% < 20% (prev 67.39%; Δ 1.72% < -1%) |
| CFO/TA 0.03 > 3% & CFO 33.1m > Net Income -27.1m |
| Net Debt (269.3m) to EBITDA (53.8m): 5.00 < 3 |
| Current Ratio: 2.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (314.4m) vs 12m ago 5.12% < -2% |
| Gross Margin: 87.91% > 18% (prev 0.90%; Δ 8.70k% > 0.5%) |
| Asset Turnover: 73.11% > 50% (prev 67.30%; Δ 5.82% > 0%) |
| Interest Coverage Ratio: 1.00 > 6 (EBITDA TTM 53.8m / Interest Expense TTM 46.2m) |
Altman Z''
-10.37
| A: 0.46 (Total Current Assets 676.2m - Total Current Liabilities 237.8m) / Total Assets 949.9m |
| B: -2.91 (Retained Earnings -2.77b / Total Assets 949.9m) |
| C: 0.05 (EBIT TTM 46.4m / Avg Total Assets 867.5m) |
| D: -4.06 (Book Value of Equity -2.74b / Total Liabilities 675.6m) |
| Altman-Z'' Score: -10.37 = D |
Beneish M
-3.08
| DSRI: 0.95 (Receivables 115.3m/101.1m, Revenue 634.2m/528.3m) |
| GMI: 1.02 (GM 87.91% / 89.98%) |
| AQI: 0.81 (AQ_t 0.24 / AQ_t-1 0.29) |
| SGI: 1.20 (Revenue 634.2m / 528.3m) |
| TATA: -0.06 (NI -27.1m - CFO 33.1m) / TA 949.9m) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of FOLD shares?
As of April 07, 2026, the stock is trading at USD 14.44 with a total of 2,991,100 shares traded.
Over the past week, the price has changed by +0.14%, over one month by +0.77%, over three months by +1.19% and over the past year by +102.10%.
Over the past week, the price has changed by +0.14%, over one month by +0.77%, over three months by +1.19% and over the past year by +102.10%.
Is FOLD a buy, sell or hold?
Amicus Therapeutics has received a consensus analysts rating of 4.42.
Therefore, it is recommended to buy FOLD.
- StrongBuy: 8
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the FOLD price?
| Analysts Target Price | 14.5 | 0.4% |
Amicus Therapeutics (FOLD) - Fundamental Data Overview
as of 06 April 2026
P/E Forward = 30.4878 P/S = 7.1493
P/B = 16.5278
P/EG = -0.18
Revenue TTM = 634.2m USD
EBIT TTM = 46.4m USD
EBITDA TTM = 53.8m USD
Long Term Debt = 392.7m USD (from longTermDebt, last quarter)
Short Term Debt = 8.74m USD (from shortTermDebt, last quarter)
Debt = 483.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 269.3m USD (from netDebt column, last quarter)
Enterprise Value = 4.72b USD (4.53b + Debt 483.3m - CCE 293.5m)
Interest Coverage Ratio = 1.00 (Ebit TTM 46.4m / Interest Expense TTM 46.2m)
EV/FCF = 158.3x (Enterprise Value 4.72b / FCF TTM 29.8m)
FCF Yield = 0.63% (FCF TTM 29.8m / Enterprise Value 4.72b)
FCF Margin = 4.71% (FCF TTM 29.8m / Revenue TTM 634.2m)
Net Margin = -4.27% (Net Income TTM -27.1m / Revenue TTM 634.2m)
Gross Margin = 87.91% ((Revenue TTM 634.2m - Cost of Revenue TTM 76.7m) / Revenue TTM)
Gross Margin QoQ = 84.64% (prev 87.38%)
Tobins Q-Ratio = 4.97 (Enterprise Value 4.72b / Total Assets 949.9m)
Interest Expense / Debt = 2.36% (Interest Expense 11.4m / Debt 483.3m)
Taxrate = 46.23% (1.45m / 3.14m)
NOPAT = 24.9m (EBIT 46.4m * (1 - 46.23%))
Current Ratio = 2.84 (Total Current Assets 676.2m / Total Current Liabilities 237.8m)
Debt / Equity = 1.76 (Debt 483.3m / totalStockholderEquity, last quarter 274.2m)
Debt / EBITDA = 5.00 (Net Debt 269.3m / EBITDA 53.8m)
Debt / FCF = 9.02 (Net Debt 269.3m / FCF TTM 29.8m)
Total Stockholder Equity = 225.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.13% (Net Income -27.1m / Total Assets 949.9m)
RoE = -12.02% (Net Income TTM -27.1m / Total Stockholder Equity 225.6m)
RoCE = 7.50% (EBIT 46.4m / Capital Employed (Equity 225.6m + L.T.Debt 392.7m))
RoIC = 4.04% (NOPAT 24.9m / Invested Capital 617.3m)
WACC = 8.38% (E(4.53b)/V(5.02b) * Re(9.14%) + D(483.3m)/V(5.02b) * Rd(2.36%) * (1-Tc(0.46)))
Discount Rate = 9.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.48%
[DCF] Terminal Value 68.95% ; FCFF base≈29.8m ; Y1≈19.6m ; Y5≈8.96m
[DCF] Fair Price = N/A (negative equity: EV 166.3m - Net Debt 269.3m = -103.0m; debt exceeds intrinsic value)
EPS Correlation: 83.64 | EPS CAGR: 131.0% | SUE: -0.52 | # QB: 0
Revenue Correlation: 97.64 | Revenue CAGR: 25.63% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.02 | Chg7d=-0.136 | Chg30d=-0.136 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=0.07 | Chg7d=-0.574 | Chg30d=-0.574 | Revisions Net=-1 | Growth EPS=-76.6% | Growth Revenue=+18.6%
EPS next Year (2027-12-31): EPS=0.82 | Chg7d=-0.099 | Chg30d=-0.099 | Revisions Net=-1 | Growth EPS=+1028.8% | Growth Revenue=+18.1%
External Resources